# A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

> **NCT02264535** · PHASE4 · COMPLETED · sponsor: **Jiangsu Kanion Pharmaceutical Co., Ltd** · enrollment: 149 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** 0.1mg/ml Ginkgolides Meglumine Injection
- **DRUG:** 1mg/ml Ginkgolides Meglumine Injection
- **DRUG:** 5mg/ml Ginkgolides Meglumine Injection

## Key facts

- **NCT ID:** NCT02264535
- **Lead sponsor:** Jiangsu Kanion Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-11
- **Final completion:** —
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2014-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264535, "A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02264535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*